Pfizer CEO might be trying to scare people into getting the vaccine with his snide comments on the matter. This report surfaces as the company develops the latest variant of it’s vaccine.
As his business produces a new edition of its abortion-tainted and leaky COVID vaccination and offers it to nations, Pfizer CEO Albert Bourla claims life will “return to normal.”
On Sunday, he told the French newspaper Le Figaro that humanity might shortly “resume a normal life.”
All you have to do is go to your neighborhood drugstore or hospital at minimum once a year and get vaccinated with the Pfizer jab.
According to Midi Libre, Bourla stated COVID will indeed be “very difficult to eradicate” and might be present “for years.” He’ll have a dose for everyone (if you already possess Pfizer shares, that is).
Subscribe to GreatGameIndia
Pfizer is, quite fortunately, working on a vaccine to combat the Omicron strain.
Plus, if I had to speculate, Pfizer’s experts are developing on a Rho immunization for 2023 and a Sigma vaccine for 2024.
“It has spread all over the world, it can infect the same person several times, and it has mutated to the point of making us rediscover the Greek alphabet,” Bourla said.
“The question is not whether this virus will disappear or not … [it] is: are we going to be able to resume a normal life?”
You will, according to Bourla, provided you consume his injections.
“We are well positioned to get there in the spring thanks to all the tools at our disposal: tests, very effective vaccines, and the first treatments that can be taken at home,” he said.
According to Bourla’s previous claims, the “effective vaccines” must always be administered at minimum once a year. Obviously, those “treatments” pertain to Pfizer’s own formulations, not to less expensive and well-tested alternatives like ivermectin or hydroxychloroquine.
“The most likely scenario for me is that, because the virus is spread all over the world, that [we] will continue seeing new variants that are coming out,” Bourla predicted in September 2021.
Yet another explanation so as to why the virus could continue to propagate amidst the fact that a vaccine has been available for more than a year is because the vaccines are ineffective at halting transmission.
“Our vaccines are working exceptionally well. They continue to work well with Delta with regard to severe illness and death,” Centers for Disease Control and Prevention Director Walensky told CNN. “But what they can’t do anymore is prevent transmission.”
COVID vaccination trials haven’t ever yielded proof that the vaccinations prevent infection or transmission. Eliminating transmission isn’t really a criterion for success; rather, avoiding severe COVID-19 illness signs is.
“Also, we will have vaccines that they will last at least a year, and I think the most likely scenario is annual vaccination, but we don’t know really, we need to wait and see the data,” Bourla told ABC News.
The term “data” most likely relates to the profit margin and governments’ willingness to continue purchasing Pfizer vaccines.
According to analysts, Pfizer might generate over $100 billion in revenue by 2022.
According to the Wall Street Journal, Pfizer has also created a COVID medication termed Paxlovid over which the US federal government has committed to pay billions of dollars.
According to a financial consultant, the persistent dread of COVID, which would involve boosters in children as young as five years old, would certainly financially advantage Bourla and his corporation, which might generate over $100 billion in revenue by 2022.
Analyst Geoffrey Porges projected, according to Markets Insider’s summary, that “Pfizer’s top line will exceed $100 billion in 2022 compared to $82 billion this year, thanks to incremental revenue contributions from Comirnaty and Paxlovid.”
“Universal boosting and pediatric recommendations, the analyst said, should boost COVID-19 vaccine revenue,” Market Insider continued.
“The analyst estimates $59 billion in 2021 COVID vaccine sales and $48 billion in 2022 globally.”
Nonetheless, Paxlovid, Pfizer’s therapy for a disease that mostly kills the elderly and those with underlying illnesses, comes with a long list of limitations.
People who have renal or liver problems should not use it. It can’t be given for COVID patients who are in the hospital, and it must to be administered within three days after the onset of symptoms.
The medicine was mostly tested on otherwise healthy persons, with only 21% of those studied possessing a condition.
According to Johns Hopkins University’s COVID mortality estimates, 98.5 percent of all COVID patients will live. People of all ages and medical conditions are included in the tally.